Oncolytics Biotech Inc.

Since its incorporation in 1998, Oncolytics Biotech Inc. has focused on the research and commercialization of innovative oncology treatments from its headquarters in Calgary, Canada. As a clinical-stage biopharmaceutical company, it develops therapies that harness the power of the immune system to fight cancer. By targeting specific biological pathways, the company aims to improve outcomes for patients with various aggressive forms of the disease.

The company’s lead development candidate, pelareorep, operates as an intravenously delivered immunotherapeutic agent. This treatment specifically targets hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) advanced and metastatic breast cancer. Furthermore, Oncolytics evaluates the drug’s potential in treating metastatic pancreatic ductal adenocarcinoma and anal cancer. This therapeutic approach focuses on activating a patient’s own immune response to recognize and destroy tumor cells.

To accelerate its clinical trials, the company maintains a strategic agreement with Roche Holding AG. This partnership secures the supply of atezolizumab, a prominent immune checkpoint inhibitor, for use in ongoing sponsored studies. Oncolytics Biotech Inc. combines internal research with global collaborations to advance its pipeline and bring new hope to patients in the oncology space.